Check out the recap from John Roy, Ph.D.'s latest podcast with Oren Hershkovitz, CEO of Enlivex Ltd. (NASDAQ: $ENLV). Those interested can listen to the podcast on all platforms or on our website. Links are accessible in our full report! $ENLV #Enlivex# #Biotech# #Immunotherapy# #DigitalAssets# #Crypto# #Blockchain# #PredictionMarkets# #HealthcareInnovation# #ClinicalTrials# #DrugDevelopment# #Web3# #Tokenization# #SmallCapStocks# #InvestorInsights# #WaterTowerResearch# @Enlivex

$CRL (Charles River Labs-Drug Development/Research) was today's top performing $SPX name, higher by +11.36%. This weekly chart by #IBD# helps to put this move into perspective This week has helped the stock rise to the highest level since '24 and also making steady progress since it peaked back in '21. Good move on both a daily and weekly basis in this Healthcare name- @IBDinvestors @marketsurge as it gradually recovers its decline from 2021

🤖 NEW: Anthropic is working with six organizations to accelerate drug development using Claude and has launched its own drug discovery programs targeting rare childhood forms of muscular dystrophy.

ANTHROPIC BUILDS BIOLOGY LAB TO PUSH AI INTO DRUG DEVELOPMENT Anthropic has quietly established a Bay Area wet lab, moving its life-sciences ambitions beyond computer simulations and into physical biological experiments. The company wants Claude to direct laboratory robots with limited human intervention, potentially accelerating research into rare and traditionally “undruggable” diseases. Anthropic says it will focus on preclinical research rather than clinical trials, avoiding direct competition with pharmaceutical companies.